INmune Bio Announces Publication of Myeloid-Derived Suppressor Cells (MDSC) Report in the Cell’s Trends in Pharmacological Sciences Journal
December 07, 2018 09:00 ET
|
INmune Bio, Inc.
Manuscript highlights the vital role of MDSC in the tumor microenvironment (TME) LA JOLLA, Calif.,, Dec. 07, 2018 (GLOBE NEWSWIRE) -- INmune Bio Inc., an immunotherapy company developing...
INmune Nominated for Buzz of Bio Award at 2019 CEO & Investor Conference
December 04, 2018 08:30 ET
|
INmune Bio, Inc.
-Voting begins today: Click here to cast your vote- LA JOLLA, Calif., Dec. 04, 2018 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunotherapy company focused on developing therapies that harness...
University of Tennessee Haslam College of Business Recognizes Provectus Biopharmaceuticals Chairman Ed Pershing as 2018 Outstanding Entrepreneur
November 12, 2018 09:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that Ed Pershing, CPA, the Chairman of the Company’s board of directors, was recognized by the Haslam...
PROVECTUS ANNOUNCES PRESENTATION OF UPDATED RESULTS FROM PHASE 1B TRIAL OF PV-10 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR TREATMENT OF ADVANCED MELANOMA AT SMR 2018 CONGRESS
October 25, 2018 08:00 ET
|
Provectus Biopharmaceuticals Inc.
- Single-agent adverse effect profiles of PV-10 and Keytruda were maintained - 65% overall objective response rate with 9% complete response, via RECIST 1.1 KNOXVILLE, TN, Oct. 25, 2018 ...
PROVECTUS BIOPHARMACEUTICALS EXPANDS PATENT PORTFOLIO WITH ADOPTIVE CELL TRANSFER-BASED USE OF INVESTIGATIONAL CANCER DRUG
September 18, 2018 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed the Company’s patent application for...
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES ACCEPTANCE OF PV-10 POSTER PRESENTATIONS AT SMR 2018 CONGRESS
September 11, 2018 09:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from two ongoing clinical trials, single agent PV-10 and PV-10 in combination with checkpoint...
PROVECTUS BIOPHARMACEUTICALS CLINICAL TRIALS UPDATE PROVIDED AT EUROPEAN POST-CHICAGO MELANOMA/SKIN CANCER MEETING
July 10, 2018 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, July 10, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that a clinical trials update was provided at the 8th European Post-Chicago Melanoma/Skin Cancer Meeting,...
PROVECTUS BIOPHARMACEUTICALS COMPLETES ENROLLMENT OF PHASE 1B TRIAL OF PV-10 IN COMBINATION WITH KEYTRUDA® IN PATIENTS WITH METASTATIC MELANOMA
May 07, 2018 08:00 ET
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE Data presentation planned for first half of 2019 KNOXVILLE, TN, May 07, 2018 (GLOBE NEWSWIRE) -- Provectus today announced the completion of enrollment of 24 patients...
STUDY OF T CELL MEDIATED IMMUNITY FROM COMBINATION OF PV-10 AND IMMUNE CHECKPOINT BLOCKADE IN MURINE MELANOMA MODELS PUBLISHED IN PLOS ONE
April 30, 2018 09:00 ET
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE Combinations with PV-10 included + anti-CTLA-4; + anti-PD-1; + anti-PD-L1; and, + anti-PD-1 + Treg depletion Data provided basis for ongoing Phase 1b/2 study of PV-10 in...
PROVECTUS BIOPHARMACEUTICALS AND PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTICS INVESTIGATORS' CONSORTIUM (POETIC) ANNOUNCE ACCEPTANCE OF PV-10 POSTER PRESENTATION AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
April 25, 2018 16:00 ET
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE Preclinical pediatric cancer research undertaken at POETIC member institutions Alberta Children’s Hospital (Canada) and Memorial Sloan Kettering Cancer Center KNOXVILLE,...